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Abstract Proprotein convertase subtilisin/kexin type 9
(PCSK9) is a member of the subtilases that promotes the
internalization and degradation of LDL receptor in liver and
thereby controls the level of LDL cholesterol in plasma.
Here, we show that the expression of PCSK9 in HepG2 cells
is completely dependent on the absence or presence of ste-
rols. The minimal promoter region of the PCSK9 gene con-
tains a sterol-regulatory element (SRE), which makes the
transcription of PCSK9 dependent on sterols. Expression of
nuclear forms of sterol-regulatory element binding protein-
1 (SREBP-1) and SREBP-2 dramatically increased the pro-
moter activity of PCSK9. In vitro-translated nuclear forms
of SREBPs showed interactions with SRE, whereas muta-
tions in SRE abolished their binding. In vivo studies in mice
showed that Pcsk9 protein and mRNA were decreased sig-
nificantly by fasting and increased by refeeding. However,
supplementation with 2% cholesterol in the diet prevented
the increase in Pcsk9. The amounts of Pcsk9mRNA in livers
of refed mice showed correlated regulation by the changes
in the nuclear form of Srebp-2. In summary, it is sug-
gested that the expression of PCSK9 is regulated by sterol
at the transcriptional level in HepG2 cells and that both
SREBP-1 and SREBP-2 can transcriptionally activate PCSK9
via SRE in its proximal promoter region in vitro. However,
in vivo, it is suggested that the sterol-dependent regulation
of PCSK9 is mediated predominantly by SREBP-2.—Jeong,
H. J., H-S. Lee, K-S. Kim, Y-K. Kim, D. Yoon, and S. W. Park.
Sterol-dependent regulation of proprotein convertase
subtilisin/kexin type 9 expression by sterol-regulatory ele-
ment binding protein-2. J. Lipid Res. 2008. 49: 399–409.
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Proprotein convertase subtilisin/kexin type 9 (PCSK9)
is a member of the proteinase K subfamily of subtilisin
serine proteases of which the gain-of-function mutations
cause hypercholesterolemia (1–3). PCSK9 was indepen-
dently identified as one of the genes that are regulated by
sterol-regulatory element binding proteins (SREBPs) (4, 5).
The SREBPs are members of the basic helix-loop-helix
leucine zipper family of transcription factors that regulate
the expression of the target genes by binding to the sterol-
regulatory elements (SREs) in their promoter regions (6).
Using microarrays hybridized with RNA from livers of mice
that either overexpressed nuclear forms of human SREBPs
(transgenic model) or lacked SREBP-activating protein
(knockout model), PCSK9 was identified as a SREBP tar-
get gene. Soon after the first cloning of this gene, with its
relationship to neural apoptosis and liver regeneration,
studies focused on its relationship with the regulation of
cholesterol in plasma. Subsequently, the loss-of-function
mutations of PCSK9 have been reported to decrease LDL
cholesterol level (7–9) and reduce the risk of coronary
heart disease (10). The definite evidence for a role of
PCSK9 in LDL metabolism was revealed by a set of in vivo
animal experiments. Adenovirus-mediated overexpression
of PCSK9 reduced the amount of low density lipoprotein
receptor (LDLR) in livers posttranscriptionally (11, 12),
whereas the amount of LDLR increased significantly in
livers of Pcsk9 knockout mice (13). The mechanism by
which PCSK9 reduces LDLR suggests that secreted PCSK9
in plasma interacts directly with LDLR protein on the
cell surface (14) and functions as a chaperone to prevent
Manuscript received 4 October 2007 and in revised form 31 October 2007.
Published, JLR Papers in Press, November 21, 2007.
DOI 10.1194/jlr.M700443-JLR200
Abbreviations: DLPS, delipidated serum; EMSA, electrophoretic
mobility shift assay; LDLR, low density lipoprotein receptor; Ni-NTA,
nickel-nitrilotriacetic acid; PCSK9, proprotein convertase subtilisin/
kexin type 9; SRE, sterol-regulatory element; SREBP, sterol-regulatory
element binding protein.
1To whom correspondence should be addressed.
e-mail: swpark64@yumc.yonsei.ac.kr
The online version of this article (available at http://www.jlr.org)
contains supplementary data.
Copyright D 2008 by the American Society for Biochemistry and Molecular Biology, Inc.
This article is available online at http://www.jlr.org Journal of Lipid Research Volume 49, 2008 399
 at Yonsei University M
edical Library, on O
ctober 27, 2014
w
w
w
.jlr.org
D
ow
nloaded from
 
0.DC1.html 
http://www.jlr.org/content/suppl/2007/12/11/M700443-JLR20
Supplemental Material can be found at:
LDLR recycling and/or to target LDLR for lysosomal deg-
radation (15).
Although several studies have focused on the impor-
tance of the posttranslational regulation of PCSK9, less
is known about the transcriptional regulation of PCSK9,
despite its identification as a gene regulated by SREBPs.
Dubuc et al. (16) reported that the transcription of PCSK9
was increased by statins, most likely through SREBP-2 ac-
tivation in primary human hepatocytes, and proposed the
importance of conserved SRE in the promoter region
of mouse, rat, and human PCSK9 genes. Costet et al. (17)
reported that insulin increased PCSK9 via SREBP-1c in
primary mouse and rat hepatocytes, as well as in vivo, dur-
ing hyperinsulinemic-euglycemic clamp procedures per-
formed on mice. However, the critical changes in the
nuclear forms of both SREBP-1 and SREBP-2 proteins in
coordination with the changes in PCSK9 protein, mRNA,
and promoter activity have not been described yet. In this
report, we show that the expression of PCSK9 is dependent
on the absence or presence of sterols via SRE in the mini-
mal promoter region of the human PCSK9 gene by both
SREBP-1 and SREBP-2 in HepG2 cells. Finally, we propose
that the predominant transcriptional regulator of PCSK9
by cholesterol is SREBP-2 in vivo.
MATERIALS AND METHODS
General methods and supplies
DNA manipulations were performed using standard molec-
ular biology techniques (18). Delipidated serum (DLPS) was
prepared from FBS as described by Hannah et al. (19). Protein
concentrations were determined using a BCA Kit (Pierce,
Rockford, IL). Cell culture medium and reagents were obtained
from Invitrogen (Carlsbad, CA). Nickel-nitrilotriacetic acid (Ni-
NTA) Sepharose was obtained from GE Healthcare Bio-Science
(Piscataway, NJ). N -Acetyl-leucine-leucine-norleucinal was ob-
tained from Merck Biosciences (Calbiochem, San Diego, CA).
Lovastatin was kindly provided byMerck and Co., Inc. (Rahway, NJ).
Sodium mevalonate was prepared from the mevalonic acid lac-
tone (Sigma-Aldrich Co., St. Louis, MO) as follows. To prepare
1.0 M sodium mevalonate, 5 g of mevalonic acid lactone was dis-
solved in distilled water, then 4 ml of 10 N NaOH was added drop-
wise and stirred for 30 min at room temperature. The pH of the
solution was adjusted by 0.5 N HCl to pH 7.5, then the final volume
was brought to 38.4 ml with distilled water. The stock solution was
filter-sterilized, divided into aliquots, and stored at 220jC until
use. Other reagents not specified were obtained from Sigma. The
following antibodies were used in the current studies: anti-HSV
from Merck Biosciences (Novagen, Madison, WI), and anti-
GAPDH and anti-cAMP-response element binding protein from
Cell Signaling Technology, Inc. (Beverly, MA). Horseradish
peroxidase-conjugated secondary antibodies were obtained from
Pierce. The polyclonal antibodies against human SREBP-1 (#932),
which has cross-reactivity tomouse Srebp-1, mouse Srebp-2 (#841),
bovine ldlr (#3143), and receptor-associated protein (#692), were
kindly provided by Jay Horton (Department of Molecular Genetics,
University of Texas Southwestern Medical Center at Dallas).
Construction of promoter-reporter plasmids
We arbitrarily annotated the first base of the translated ATG
as 11, as described by Costet et al. (17). The human PCSK9 pro-
moter fragment spanning 22,112 to 294 was amplified by PCR
from the human genomic DNA isolated from leukocytes using
the following primers: 5¶-AAGAGGCATTTAGGGATAAGAGG-3¶
and 5¶-ACTGTGCAGGAGCTGAAGTTCAG-3¶. The amplified
DNA product was gel-purified using the QiaQuick PCR purifi-
cation kit (Qiagen, Inc., Valencia, CA) and cloned using the
pCR2.1-TOPO TA cloning kit (Invitrogen). After the integrity of
the amplified DNA sequences was verified by DNA sequencing,
this plasmid was used as the template for the PCR amplification
of deletion fragments (for details, see supplementary methods).
Briefly, the promoter fragment for each deletion clone (D1–D7)
was amplified by PCR with the respective primers, gel-purified,
and cloned using the pCR2.1-TOPO TA cloning kit (Invitrogen).
After the orientation of the promoter fragments inserted in
pCR2.1 vector was verified by DNA sequencing, the promoter
fragments were subcloned into pGL3-Basic vector (Promega,
Madison, WI) to produce deletion clones of PCSK9 promoter-
reporter constructs. The SREmutant (SRE-Mut) and Sp1 mutants
(Sp1-Mut1–Sp1-Mut5) were generated from construct D4 using
the QuickChange site-directed mutagenesis kit (Stratagene) and
the respective oligonucleotides as described in the supplementary
methods. The integrity of promoter-reporter plasmid sequences
was confirmed by DNA sequencing.
Construction of expression plasmids
The bacterial expression plasmids that were used for the pro-
duction of antibodies against human PCSK9 (amino acids 153–
692) or mouse Pcsk9 (amino acids 156–694) were constructed as
follows. Human PCSK9 cDNA was amplified by PCR using pCMV-
PCSK9-FLAG (12) as the template with the following primers:
5¶-ACCATGGAATTCAGCATCCCGTGGAACCTG-3¶ and 5¶-CCG-
CCTCTCGAGCTGGAGCTCCTGGGAGGC-3¶. The amplified
DNA was digested with EcoRI and XhoI, then ligated into the
pET-21a(1) vector (Novagen). Mouse Pcsk9 cDNA was amplified
by PCR using the template cDNA prepared from livers of fasted/
refed mice with the following primers: 5¶-GTCGACAGCATCC-
CATGGAACCTGG-3¶ and 5¶-CTTCTCAAGCTTCTAGTGATGG-
TGATGGTGATGCTGAACCCAGGAGGCCTTTG-3 ¶. The
amplified DNA was gel-purified and ligated into pCR2.1-Topo
cloning vector (Invitrogen). The plasmid with cDNA in the cor-
rect orientation was selected, and the cDNA was subcloned into
pET-21a(1) vector after digestion with EcoRI and HindIII. The
other expression plasmids used in this experiment are described
in the supplementary methods. The following plasmids were
constructed: the plasmids that were used in cotransfection exper-
iments, encoding HSV epitope-tagged nuclear forms of human
SREBP-1a (pTK-HSV-nBP1a), SREBP-1c (pTK-HSV-nBP1c), and
SREBP-2 (pTK-HSV-nBP2), the expression of which is under the
control of the thymidine kinase promoter; the plasmids that were
used as templates for the in vitro translation of nuclear forms
of SREBPs (pCMV-nBP1a and pCMV-nBP2); the bacterial expres-
sion plasmid used for the production of antibodies against
human SREBP-2, pET-nhBP2-DHLH, encoding the nuclear form
of human SREBP-2 (amino acids 14–330) lacking its helix-
loop-helix domain. The integrity of each plasmid was confirmed
by DNA sequencing.
Antibody preparation
The antibodies against human PCSK9, mouse Pcsk9, and
human SREBP-2 were prepared using recombinant proteins ac-
cording to standard procedures. The recombinant proteins were
expressed in Escherichia coli BL21 by induction with 0.5 mM
isopropyl-b-thiogalactopyranoside and purified by affinity chroma-
tography with Ni-NTA Sepharose (GE Healthcare Bio-Science)
under denaturing conditions according to the manufacturer’s
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instructions. The proteins were further purified by electropho-
resis on 10% SDS-polyacrylamide gels, and the bands corre-
sponding to the size of each protein were cut and homogenized
with a minimum volume of 0.9% (w/v) NaCl using a Polytron
homogenizer. The amounts corresponding to 500 mg of purified
proteins were injected at least seven times at 3-week intervals
into male New Zealand White rabbits. The specificity of SREBP-2
antiserum to discriminate SREBP-1 and SREBP-2 was verified
by immunoblotting using the in vitro-translated nuclear forms
of SREBP-1a and SREBP-2 (described above), which have no
6-His epitope.
Cell culture, transient transfection, and reporter
gene assay
HepG2 (American Type Culture Collection number HB-8065)
cells were maintained inmediumA (DMEM containing 100 U/ml
penicillin and 100 mg/ml streptomycin sulfate) supplemented
with 10% (v/v) FBS. Transfection of DNA into HepG2 cells in
suspension was carried out using Lipofectamine Plus Reagent
(Invitrogen) according to the method described by Notarangelo
et al. (20) with minor modifications. Briefly, plasmids were com-
plexed using Lipofectamine Plus Reagent (Invitrogen) according
to the manufacturer’s instructions in Opti-MEM (Invitrogen).
While the DNA-Lipofectamine complex was prepared, HepG2
cells were trypsinized and suspended inmedium A supplemented
with 10% FBS. The DNA-Lipofectamine complex was mixed with
2 3 105 cells per well/12-well plate in 0.75 ml of medium A sup-
plemented with 10% FBS and rocked for 40 min at 37jC in the
tube. The mixtures were plated on 12-well plates and cultured
overnight at 37jC under a humidified atmosphere of 5% CO2.
For the treatment of cells with or without sterols, on day 1,
cells were washed twice with PBS and changed to medium A
supplemented with 10% DLPS, 1 mM lovastatin, and 50 mM
sodium mevalonate in the absence or presence of 1 mg/ml
25-hydroxycholesterol plus 10 mg/ml cholesterol added in a final
concentration of 0.2% (v/v) ethanol. On day 2, cells were washed
twice with PBS, harvested, and analyzed for luciferase activity
using the dual-luciferase assay system with passive lysis buffer
(Promega) according to the manufacturer’s instructions. The
firefly luciferase activity was normalized to the renilla luciferase
activity and the amounts of protein in the lysate.
Immunoblot analysis
HepG2 cells were set up and treated as described in the figure
legends. After treatment, cells were washed twice with PBS and
lysed with 100 ml of NUN buffer (21) containing 0.33 M NaCl,
1.1 M urea, 1% Nonidet P-40, 25 mM HEPES (pH 7.6), and
proteinase inhibitors (1 mM DTT, 10 mg/ml leupeptin, 5 mg/ml
pepstatin A, 1 mM PMSF, 2 mg/ml aprotinin, and 50 mg/ml
N -acetyl-leucine-leucine-norleucinal) by adding directly onto the
plate. Cell lysates were harvested and further vortexed at room
temperature for 10 min for the complete liberation of proteins.
Lysate were cleared by centrifugation at 20,000 g for 15 min at
4jC, and the supernatants were collected as whole cell lysate.
For immunoblot analyses of mouse liver proteins, the membrane
and nuclear fractions were prepared as described (12) except
for the following modification. The membrane pellets were re-
suspended in NUN buffer, vortexed for 10 min at room
temperature, and centrifuged at 20,000 g for 15 min at 4jC,
and the supernatants were collected as the membrane fractions.
After quantitation of proteins, aliquots of proteins were subjected
to 8% SDS-PAGE and transferred onto nitrocellulose ECL
membranes (GE Healthcare), and immunoblot analyses were
performed using the SuperSignal West Pico Chemiluminescent
Substrate System (Pierce).
Quantitative real time-PCR
Total RNA was prepared from HepG2 cells or livers of mice
using an RNeasy Mini kit (Qiagen) or Trizol reagent (Invitrogen),
respectively. Removal of DNA from RNA was achieved with RNase-
free DNase (Qiagen) for RNA from cells or a DNA-free kit (Ambion,
Austin, TX) for RNA from tissues. cDNA was synthesized from
2 mg of DNase-treated total RNA using a High-Capacity cDNA
Archive kit (Applied Biosystems, Foster City, CA). Quantitative
real-time PCR was performed as described previously (12) using
the RG-3000 Rotor-Gene (Corbett Research, Sydney, Australia).
All reactions were done in triplicate, and the relative amounts of
all mRNAs were calculated by the comparative cycle-time method
(22). Cyclophilin mRNA was used as the invariant control. Spe-
cific primers for each gene were described previously (16, 23).
The sequences of primers for human PCSK9, and cyclophilin were
as follows: human PCSK9, 5¶-GGCAGGTTGGCAGCTGTTT-3¶ and
5¶-CGTGTAGGCCCCGAGTGT-3¶; human cyclophilin, 5¶-GGA-
GATGGCACAGGAGGAAA-3¶ and 5¶-CCGTAGTGCTTCAGTTT-
GAAGTTCT-3¶.
Electrophoretic mobility shift assay
Nuclear forms of human SREBP-1a and SREBP-2 were gener-
ated from pCMV-nBP1a and pCMV-nBP2 (detailed procedures
are described in the supplementary methods) using the TNT
Quick Coupled Transcription/Translation system (Promega) ac-
cording to the manufacturer’s instructions. The DNA probe was
double-stranded oligonucleotides derived from the wild-type se-
quence found between 2360 and 2327 relative to the first ATG
codon in the PCSK9 promoter sequence. Sequences of the wild-
type and the mutant SRE probe are shown in Fig. 5A below. The
DNA probe was prepared as follows. The 3¶-biotinylated oligonu-
cleotide was hybridized to a 3-fold molar excess of the unlabeled
complementary strand in 50 mM Tris-Cl, pH 7.9, 50 mM NaCl,
and 10 mM MgCl2 by incubation at 65jC for 10 min and cooling
at room temperature for 30 min. Binding reactions were per-
formed in a total volume of 20 ml using a LightShift Chemilumi-
nescent electrophoretic mobility shift assay (EMSA) kit (Pierce)
according to the manufacturer’s instructions, with minor modi-
fications. Two hundred femtomoles of labeled probes and 1 ml of
in vitro transcription/translated protein were complexed by in-
cubation at room temperature for 30 min. The DNA-protein
complexes were subjected to electrophoresis on a 6% TBE Gel
Retardation Gel (Invitrogen) in 0.53 TBE buffer (80 V, 40 min
at room temperature), transferred onto the positively charged
nylon membrane (GE Healthcare), UV cross-linked, and visu-
alized by a Chemiluminescent Nucleic Acid Detection Module
(Pierce). For the antibody supershift assay, 1 ml of anti-human
SREBPs or nonimmune rabbit serum was added to the reaction
after the formation of the DNA-protein complex and incubated
at room temperature for another 15 min before electrophoresis.
For the oligonucleotide competition assay, the competing un-
labeled double-stranded oligonucleotide was added to the reac-
tion with the biotin-labeled probe at 0.2- to 25-fold molar excesses.
Mice and diet
Eight-week-old male C57B/6 mice purchased from Japan
SLC, Inc. (Shizuoka Prefecture, Japan) were maintained on 12 h
dark/12 h light cycles and fed a chow diet (Rodent Diet from SCF
Co., Inchon, Korea) that contained 5.9% (w/w) crude fat and
,0.06% (w/w) cholesterol. The nonfasted group was fed a chow
diet ad libitum, the fasted group was fasted for 24 h, and the refed
groups were fasted for 24 h and then refed the indicated diets for
24 h before euthanasia. The starting times for the experiments
were staggered so that all mice were euthanized at the same time,
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which was at the end of the dark cycle. The high-sucrose diet
was prepared as described by Yang, Wang, and Chen (24). A chow
diet supplemented with 2% cholesterol was prepared as de-
scribed (25). The powdered diets were reformed into pellets with
minimal amounts of distilled water. After treatment, livers were
collected and stored at 280jC until later use. All animal ex-
periments were performed with the approval of the Institutional
Animal Care and Research Advisory Committee at Kwandong
University College of Medicine.
RESULTS
Time-course expression of PCSK9 in the presence or
absence of sterols in HepG2 cells
Several reports have shown that PCSK9 is regulated by
sterols at the transcriptional level; however, the endoge-
nous PCSK9 protein itself has not been verified to be
regulated accordingly. To determine whether PCSK9 ex-
pression is modulated by the depletion of sterols, HepG2
cells were grown in medium supplemented with 10%
DLPS for the indicated times up to 24 h. After incubation,
the cells were changed to a fresh medium supplemented
with 10% DLPS, 1 mM lovastatin, and 50 mM sodium
mevalonate in the presence or absence sterols for the in-
dicated times. Figure 1A shows that the depletion of sterols
induces PCSK9 in a time-dependent manner (lanes 1–5).
The basal level of PCSK9 was barely detectable when
HepG2 cells were grown in medium supplemented with
10% FBS (Fig. 1A, lane 1). Depletion of sterols gradually
increased the expression of PCSK9 by 12 h, and the in-
crease in PCSK9 was attenuated by 24 h (Fig. 1A, lane 6),
supposedly because of the partial restoration of sterols
synthesized endogenously in the cells. When 1 mM lova-
statin and 50 mM sodium mevalonate were supplemented
to the cells, which is a condition to suppress the endoge-
nous synthesis of sterols, PCSK9 was further increased by
24 h (Fig. 1A, lanes 7–12). When the sterols were added
to the cells, the increase in PCSK9 proteins was completely
blocked, and PCSK9 was almost undetectable by 24 h of
sterol treatment (Fig. 1A, lanes 13–18). These findings
suggest that the expression of PCSK9 is regulated by ste-
rols that are supplied endogenously or exogenously in
HepG2 cells.
The expression of LDLR followed exactly the same
pattern as that of PCSK9 when the cells were grown in the
absence of sterols (Fig. 1A, lanes 1–12), whereas the ex-
pression of LDLR was restored after 12 h of sterol supple-
mentation with lovastatin (Fig. 1A, lanes 17, 18). Nuclear
forms of SREBP-2 showed similar changes to that of PCSK9
in HepG2 cells. Accordingly, the membrane forms of
SREBP-2 showed reciprocal changes to its nuclear forms.
However, it was shown that the changes in the nuclear
form of SREBP-2 preceded the changes in PCSK9 or LDLR
by depletion of sterols. Depletion of sterols even for 2 h
resulted in increases in the amount of the nuclear form of
SREBP-2 (Fig. 1A, lane 2). They reached the highest level
by 8 h and remained constant by 12 h (Fig. 1A, lanes 4, 5).
Similar to the changes in PCSK9 and LDLR, nuclear forms
of SREBP-2 were decreased by 24 h (Fig. 1A, lane 6). Lova-
Fig. 1. Time-course expression of proprotein convertase subtilisin/
kexin type 9 (PCSK9) in HepG2 cells after depletion or supple-
mentation of sterols. A: On day 0, HepG2 cells were set up at 6 3
105 cells per 60 mm dish with medium A supplemented with 10%
FBS. On day 2, the cells were washed twice with PBS, then switched
to fresh medium A supplemented with 10% delipidated serum
(DLPS) for the indicated times (lanes 1–6). After 24 h of incu-
bation, cells were washed once with PBS, then switched to fresh
medium A supplemented with 10% DLPS, 1 mM lovastatin, and
50 mM sodiummevalonate in the absence (lanes 7–12) or presence
(lanes 13–18) of 1 mg/ml 25-hydroxycholesterol and 10 mg/ml
cholesterol. After the indicated incubation period, cells were har-
vested and lysed, and the whole cell lysates were subjected to im-
munoblot analysis with polyclonal antibodies against PCSK9, low
density lipoprotein receptor (LDLR), and sterol-regulatory ele-
ment binding protein-2 (SREBP-2). GAPDH protein was used as a
loading control. P and C for PCSK9 denote the proprotein and
cleaved forms of PCSK9, respectively. P and N for SREBP-2 denote
the precursor and cleaved nuclear forms of SREBP-2, respectively.
The asterisks indicate irrelevant cross-reacting bands. B: Total
RNAs from the cells at the indicated times were prepared and sub-
jected to reverse transcription and quantitative real-time PCR as
described in Materials and Methods. Each value represents the
amount of mRNA relative to that in the cells grown in the ab-
sence of lovastatin, mevalonate, and sterols for 24 h (corresponding
to the cells in lane 6 in A), which was arbitrarily defined as 1.
Cyclophilin was used as an invariant control (data not shown). The
values represent means from duplicate reactions. Similar results
were obtained in two independent experiments.
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statin and mevalonate significantly increased the nuclear
form of SREBP-2 by 24 h in the absence of sterol (Fig. 1A,
lanes 7–12), whereas in the presence of sterol the expres-
sion of nuclear forms of SREBP-2 vanished completely by
4 h (Fig. 1A, lanes 15–18).
To determine whether the changes in PCSK9 protein by
sterols accompany the change in PCSK9mRNA, total RNA
from the cells for each condition was isolated and analyzed
for the expression of each gene by real-time PCR (Fig. 1B).
The amount of PCSK9mRNA increased gradually for 24 h
by sterol depletion (Fig. 1B). When the cells were changed
to the fresh medium supplemented with lovastatin and
mevalonate in the absence of sterols, PCSK9 mRNA de-
creased slightly for 1 h, then increased by 4–24 h. The ad-
dition of sterols completely blocked the increase in PCSK9
mRNA by lovastatin. Lovastatin also increased LDLR
mRNA in the absence of sterols. However, LDLR mRNA
was restored by 24 h after its initial decrease by the pres-
ence of sterols. These changes in LDLR mRNA corre-
sponded to those in LDLR protein in HepG2 cells. The
changes in SREBP-2mRNA were not as obvious as those in
PCSK9 or LDLR mRNA when the cells were grown in the
absence of sterols without lovastatin. However, the evident
changes in SREBP-2 mRNA were observed when the cells
were grown with lovastatin and mevalonate. These find-
ings suggest that the expression of PCSK9 is regulated by
sterols and that this regulation is achieved at the tran-
scription level possibly mediated by SREBP-2.
Lovastatin increases the expression of PCSK9, but
mevalonate reverses the increase partially at
high concentration
To verify the effects of the inhibition of endogenous
cholesterol synthesis on PCSK9 expression, HepG2 cells
were grown inmedium supplemented with varying amounts
of lovastatin or sodium mevalonate (Fig. 2). The addition
of lovastatin increased both the proteins and mRNAs
for PCSK9, LDLR, and the nuclear form of SREBP-2 in a
concentration-dependent manner (Fig. 2A, lanes 1–6).
These changes by lovastatin were reversed by 10 mM so-
dium mevalonate (Fig. 2A, lane 12). The precursor form of
SREBP-2 protein showed the reciprocal changes to nuclear
forms. Together, these results strongly suggest that the ex-
pression of PCSK9 is regulated by sterols that are supplied
either endogenously or exogenously, and the nuclear form
of SREBP-2 is a key regulatory factor for this regulation.
Sterol-dependent regulation of the promoter activity of
the PCSK9 gene
To identify the location of functionally essential DNA
sequences that mediate the sterol-dependence of the
PCSK9 promoter, we amplified the 5¶ flanking region from
22,112 to 294 of the PCSK9 gene. This amplified DNA
was used as a template for the construction of promoter-
reporter constructs using pGL3-Basic reporter vector to
generate constructs D1–D7 (Fig. 3A). Sequence analysis
(Fig. 3B) revealed the presence of SRE at2346 and several
Sp1 binding sites in the proximal region of the PCSK9
promoter, as described previously (16, 17). The SRE site,
5¶-GTGGCGTGAT-3¶ (5¶-ATCACGCCAC-3¶ in the comple-
mentary strand), bears the identical sequences to SRE
found in the LDLR promoter, except for a single nucleo-
tide at position 6 (based on the complementary sequences),
the replacement of which in the LDLR promoter did not
affect the basal transcription or sterol-dependent regula-
tion of the LDLR promoter (26–28). The binding sites for
Sp1, whose supportive function has been reported to be
important in the SREBP-mediated transcriptional regula-
tion of many genes (29–31), were found close to the SRE
Fig. 2. Induction of PCSK9 by lovastatin and its reversal by
mevalonate. A: On day 0, HepG2 cells were set up at 4 3 105 cells
per well on six-well plates with medium A supplemented with 10%
FBS. On day 1, cells were washed twice with PBS, then switched to
fresh medium A supplemented with 10% DLPS for 24 h. On day 2,
cells were washed once with PBS, then switched to fresh medium A
supplemented with 10% DLPS and the indicated amounts of
lovastatin and/or sodium mevalonate in the absence of sterols.
After 24 h of incubation, on day 3, cells were harvested and immu-
noblot analysis was carried out as described for Fig. 1A. B: Total
RNAs from the cells were prepared and subjected to reverse tran-
scription and real-time PCR as described for Fig. 1B. Each value
represents the amount of mRNA relative to that in the cells grown
at 50 mM sodium mevalonate without lovastatin (corresponding
to the cells in lane 1 in A), which was arbitrarily defined as 1. The
values represent means 6 SD from triplicate reactions. Similar re-
sults were obtained in three independent experiments.
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site in the PCSK9 promoter. As shown in Fig. 3C, the con-
structs D1–D5 showed gradual increases in the promoter
activities when the cells were grown in sterol-depleted
conditions. The transcriptional activity of each construct
was decreased by ?95% by the presence of sterols. Dele-
tion in construct D6 dramatically decreased the promoter
activity in the absence of sterols, and the sterol-mediated
suppression of the transcription was attenuated from 95%
to 23%. Mutation of SRE in the D4 construct (SRE-Mut)
dramatically decreased the transcriptional activity of the
PCSK9 promoter in the absence of sterols; consequently,
its sterol-dependent suppression of transcription was at-
tenuated (from 95% to 41%). These results suggest that
the SRE site is important for the sterol-dependent regula-
tion of transcription of the PCSK9 promoter. Mutations in
Sp1 binding sites moderately decreased the transcription
of the PCSK9 promoter in the absence of sterols, except for
the mutation in the second Sp1 binding site (Sp1-Mut2),
which resulted in increases in the transcription of the
PCSK9 promoter. However, the sterol-dependent regula-
tion of the PCSK9 promoter was preserved in all Sp1 mu-
tants. As a result of these findings, it is suggested that the
SRE site and the adjacent upstream nucleotides are impor-
tant for the transcriptional regulation of the PCSK9 pro-
moter by sterol, whereas the Sp1 binding sites are not
critically required for this regulation.
Regulation of the promoter activity of PCSK9 by
overexpression of SREBPs
To determine whether the SRE in the PCSK9 promoter
is activated by SREBPs, the wild-type construct D4 or the
mutant form (SRE-Mut) was cotransfected into HepG2
cells with pTK-HSV-nBP1a, pTK-HSV-nBP1c, or pTK-HSV-
nBP2, and luciferase activity was measured (Fig. 4A). The
Fig. 3. Activation of the human PCSK9 promoter
by the depletion of sterols in HepG2 cells. A:
Schematic representation of the deletion constructs
of human PCSK9 promoter-luciferase reporters.
Position 21 was designated arbitrarily as the nucle-
otide preceding the ATG start codon. Position 294
is the 3¶ end of PCSK9 promoter inserts in common
to all promoter-reporter constructs. The 5¶ ends of
the promoters in each promoter-reporter construct
are marked by numbers at left, and the name of
each construct is shown at right. The putative sterol-
regulatory element (SRE; squares) and Sp1 (circles)
motifs and their respective mutants (squares or cir-
cles with a cross) in each construct are shown. B: The
sequence of the proximal human PCSK9 5¶ flanking
region (?440 bp) is shown with the putative SRE
and Sp1 motifs denoted by arrows. Below the se-
quence of the wild-type promoter are shown the
mutant nucleotide sequences (in italic capitals) for
SRE and the Sp1 motif introduced in the respec-
tive mutant constructs. C: The promoter-reporter
constructs were transfected and incubated in the
absence or presence of sterols as described in
Materials and Methods. Cells were harvested with
passive lysis buffer on day 2, and the luciferase ac-
tivities were measured. The luciferase activities were
normalized with renilla luciferase activities and
the amounts of proteins used for the assays. The
luciferase activities were calculated as the ratio of
normalized activities of the indicated constructs
relative to that of construct D4 in the absence of ste-
rols (which was arbitrarily defined as 1). Each value
represents the mean 6 SD of three independent
transfection experiments (each in triplicate reac-
tion). The mean percentage suppression by sterols
for each construct is shown in the bottom row.
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expression of nuclear forms of SREBPs was directed by the
thymidine kinase promoter to control the amounts of
expressed SREBPs in a dose-dependent manner (32). The
amounts of cotransfected expression plasmids were de-
termined to be in a range below the amounts showing the
saturation effect of activation (data not shown). The amounts
of expressed proteins were verified to be similar to each
other by immunoblot analysis (Fig. 4B). As expected, the
expression of nuclear forms of SREBPs dramatically in-
creased the transcription of the PCSK9 promoter in con-
struct D4. The expression of the nuclear form of SREBP-1c,
the activation domain of which is shorter than that in
SREBP-1a, activated the wild-type PCSK9 promoter much
less than SREBP-1a or SREBP-2. The upregulation of
PCSK9 promoter activity by SREBPs was abolished by the
mutation of SRE. These results suggest that the function of
SRE in the regulation of PCSK9 promoter activity is medi-
ated by both SREBP-1 and SREBP-2 in HepG2 cells.
Recombinant SREBPs bind to SRE in the PCSK9 promoter
To determine whether the SREBPs can bind directly to
the SRE in the PCSK9 promoter, we used in vitro-translated
nuclear forms of SREBP-1a and SREBP-2 to perform EMSA.
Figure 5A shows the wild-type and mutated sequences of
the 3¶ biotinylated probes used in EMSA. Figure 5B shows
that SREBP-1a and SREBP-2 can bind to the probes (lanes
2, 11), although the migration-retarded signals by SREBP-
2 always appeared weaker and much less clear than those
produced by SREBP-1a. The mutant SRE probe showed no
migration-retarded signals (Fig. 5B, lanes 3, 12), and un-
labeled wild-type oligonucleotide effectively competed for
the binding of SREBPs to the probe (Fig. 5B, lanes 5–7,
13–16). The retarded bands were supershifted by the ad-
dition of antibodies against SREBP-1 or SREBP-2 (Fig. 5B,
lanes 8, 17), whereas the formation of the shifted complex
was unaffected by the addition of the nonimmune serum
(Fig. 5B, lanes 9, 18). These results strongly suggest that
SRE in the PCSK9 promoter specifically binds both SREBP-
1a and SREBP-2 in vitro.
Expression of PCSK9 is downregulated in liver of mice
refed with cholesterol-supplemented diets
We finally determined the regulation of Pcsk9 in livers
of mice that were subjected to 24 h of fasting followed by
refeeding with a diet containing 2% (w/w) cholesterol for
24 h. In livers of mice, the antibody used in Fig. 6A did not
pick up the proteins of the size corresponding to the pre-
cursor form of Pcsk9. It is supposed that the amount of the
precursor form of Pcsk9 in vivo is too small to be detected
by immunoblot analysis under the conditions applied in
this experiment. Figure 6A shows that fasting the mice for
24 h abolished the expression of Pcsk9 protein (lane 2),
and refeeding a high-carbohydrate diet or chow diet nor-
malized the amount of Pcsk9 up to the level in livers of
nonfasted mice (lanes 3, 5). This restoration of Pcsk9 ex-
pression was partially blocked by supplying cholesterol in a
high-sucrose diet (Fig. 6A, lane 4) and was blocked more
efficiently when mice were refed with a chow diet with
cholesterol (Fig. 6A, lane 6). In contrast, the amount of
Ldlr in livers of mice fasted for 24 h showed insignificant
change compared with the amount in nonfasted mice
(Fig. 6A, lane 2 vs. lane 1), whereas refeeding a high-
sucrose diet or a chow diet without cholesterol slightly
reduced the expression of Ldlr (Fig. 6A, lanes 3–5). How-
ever, refeeding the mice with a chow diet supplemented
with cholesterol restored the amount of Ldlr to the level
shown in the nonfasted mice (Fig. 6A, lane 6 vs. lane 1).
These findings suggest that the amount of Ldlr in vivo
follows the changes of Pcsk9 expression reciprocally when
the mice are refed. The amounts of the nuclear form of
Srebp-1c were upregulated when the mice were refed,
regardless of the supplementation of cholesterol, whereas
the nuclear form of Srebp-2 showed suppression by cho-
lesterol (Fig. 6A, lanes 4, 6), which correlated with the
changes of Pcsk9.
To determine the changes in Pcsk9 and Ldlr mRNA by
fasting and refeeding, total RNA was isolated from the
livers of mice and real-time PCR was performed (Fig. 6B).
Fig. 4. Activation of the PCSK9 promoter by SREBPs. A: On day 0,
HepG2 cells were cotransfected with 0.2 mg of the promoter-
reporter construct (wild-type D4 or the mutant form of D4 on the
SRE site) and the indicated amounts of the plasmids expressing
nuclear forms of human SREBP-1a (pTK-HSV-nBP1a; 1a), SREBP-1c
(pTK-HSV-nBP1c; 1c), or SREBP-2 (pTK-HSV-nBP2; 2) on 12-well
plates as described in Materials and Methods. The total amounts of
transfected plasmids were adjusted to 0.3 mg per well with a mock
vector (M). On day 2, cells were harvested and luciferase activity was
assayed as described in Materials and Methods. The relative lu-
ciferase activities were calculates as the ratio of normalized activi-
ties of construct D4 cotransfected with the indicated amounts of
cotransfected expression plasmids relative to that of construct D4
cotransfected with mock plasmid (which was arbitrarily defined as
1; M). Each value represents the mean 6 SD of three independent
transfection experiments (each in triplicate reaction). B: A sepa-
rate set of cells processed as described for A was used for im-
munoblot analysis with monoclonal anti-HSV antibody to verify
the expression of the recombinant proteins produced from the
cotransfected expression constructs shown under the graph. GAPDH
was used as a loading control.
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The changes in Pcsk9 mRNA corresponded to those in
Pcsk9 proteins: fasting dramatically decreased Pcsk9
mRNA; refeeding restored Pcsk9 mRNA; and supplemen-
tation of cholesterol partially blocked the restoration of
Pcsk9 mRNA. Ldlr mRNA remained relatively unchanged
by fasting and refeeding. Nevertheless, Ldlr mRNA was
downregulated when the mice were refed a diet supple-
mented with cholesterol.
We next determined the changes in the other genes
involved in fatty acid and cholesterol biosynthesis, the
transcription of which is under the control of Srebps, to
compare the effect of cholesterol on the transcription of
each gene. The mRNA for HMG-CoA reductase (Hmgcr),
one of the well-characterized Srebp-2 target genes (33),
showed downregulation by supplementation of choles-
terol. The changes of mRNAs for three lipogenic enzymes,
acetyl-CoA carboxylase a (Acaca) (34), fatty acid synthase
(Fasn) (35), and stearoyl-CoA desaturase-1 (Scd-1) (36), as
Srebp-1 target genes were also determined. The mRNAs
for Acaca, Fasn, and Scd-1 showed downregulation by fast-
ing, whereas drastic increases in their mRNAs were ob-
served by refeeding a high-sucrose diet. Most importantly,
the transcription of these Srebp-1 target genes was not
downregulated by cholesterol in livers of mice. Together,
these data suggest that the regulation of Pcsk9 expression
by cholesterol in vivo is achieved at the transcription level
and that Srebp-2 predominantly mediates this regulation.
DISCUSSION
PCSK9 has been reported as one of the genes whose
transcription is under the control of SREBPs (4, 5). Con-
sidering the function of PCSK9 in cholesterol metabolism,
it is suggested that the major regulator of its expression
is SREBP-2 (16), whereas experiments in mice that were
fasted followed by refeeding with a carbohydrate-rich diet
showed the involvement of SREBP-1 in the activation of
PCSK9 expression (17). This regulation of PCSK9 tran-
scription by SREBPs has been supported by the presence
of SRE on the promoter region of the PCSK9 gene. How-
ever, most importantly, no clear-cut evidence for the regu-
lation of endogenous PCSK9 proteins by sterols has been
provided. In the present experiments, we produced the
polyclonal antibody against PCSK9 and determined the
regulation of endogenous PCSK9 expression by sterols
and lovastatin. The expression PCSK9 protein has proven
to be induced when HepG2 cells were deprived of sterols.
Fig. 5. Binding of SREBP-1a and SREBP-2 to the SRE site in the PCSK9 promoter. A: Nucleotide sequences
of the sense strand for wild-type and mutant SRE probes. The locations of the SRE and mutated nucleotides
are indicated with the arrow and dots, respectively. Each strand was synthesized with modification of
3¶-biotinylation, and the double strand probes were produced by annealing with a 3-fold molar excess of the
respective unlabeled antisense strands as described in Materials and Methods. B: Electrophoretic mobility
shift assay using the wild-type (WT) or mutant (Mu) biotinylated probes with in vitro-translated nuclear
human SREBP-1a (BP-1a) or SREBP-2 (BP-2) protein was performed as described in Materials and Methods.
Protein Mo indicates the in vitro translation reaction using mock pcDNA3 vector. For competition assay
(Competitor), competing unlabeled double-stranded oligonucleotides were added to the reaction with the
biotin-labeled probe at 0.2- to 25-fold molar excess. For supershift assays, antiserum against SREBP-1 (BP-1)
or SREBP-2 (BP-2) was incubated with the complex for an additional 15 min. Antibody Pre indicates the
nonimmune rabbit serum. The arrow and arrowheads indicate the shifted and supershifted bands, respec-
tively. The asterisks and double asterisks indicate the shifted bands produced by the nonspecific interaction
of probes with proteins and free probes, respectively.
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When the endogenous supply of sterols was blocked by
lovastatin with a limited amount of mevalonate to supply
nonsterol isoprenoid compounds (37, 38), the induction
of PCSK9 was augmented. The increase in PCSK9 caused
by the depletion of sterols was blocked completely by the
addition of sterols in the culture medium. These changes
in PCSK9 protein by sterols paralleled thoroughly the
changes in its mRNA. The changes in the nuclear forms of
SREBP-2 by sterols were similar to those of PCSK9, how-
ever, they preceded the changes in PCSK9 expression
suggesting the possible involvement of SREBP2 in this reg-
ulation. Lovastatin, which has been reported to increase
the transcription of PCSK9 (16), has proven to increase the
expression of PCSK9 protein and mRNA even at low con-
centrations (8–40 nM). This induction of PCSK9 by lova-
statin was reversed by a very high concentration (10 mM)
of mevalonate. These findings suggest that the regulation
of PCSK9 expression is dependent on the presence or ab-
sence of sterols, which are supplied either exogenously or
endogenously, and that this regulation is achieved at the
transcription level.
The expression of LDLR showed similar changes to
PCSK9 in HepG2 cells under the sterol-depleted condi-
tions. Considering that the function of PCSK9 is to pro-
mote the degradation of LDLR (39), the parallel change
in LDLR to PCSK9 by sterols in HepG2 cells should be
interpreted as a paradox. One possible explanation for
this paradox is that the sterol-depleted condition applied
in this experiment is too stringent to show the reciprocal
regulation of LDLR and PCSK9 proteins. When the cells
are deprived of sterols, the increased expression of the
nuclear form of SREBP-2 might induce the expression
of both PCSK9 and LDLR to a level that overwhelms the
reciprocal regulation of these proteins. This hypothesis
could be supported by the finding that supplementation
of sterols to the cells for 24 h resulted in the partial res-
toration of LDLR protein and mRNA, whereas the expres-
sion of PCSK9 and the nuclear form of SREBP-2 remained
completely suppressed. Another possibility, that of lacking
a component or machinery in HepG2 cells to coordinate
the expression of these proteins, remains to be uncovered.
To clarify the transcriptional regulation of PCSK9 by
SREBPs, we cloned the 5¶ flanking region of human PCSK9
and determined its promoter activities. As reported previ-
ously by Dubuc et al. (16), the SRE site in the PCSK9 pro-
moter has proven to be important in the sterol-dependent
regulation of PCSK9 transcription in HepG2 cells. Muta-
tions of the SRE site in the PCSK9 promoter dramatically
Fig. 6. Effects of cholesterol feeding on the expression of Pcsk9 and Ldlr. A: For each group, six male C57BL/6J mice were used for
immunoblot analysis and real-time PCR. The nonfasted group was fed a chow diet ad libitum, the fasted group was fasted for 24 h before
study, and the refed groups were fasted for 24 h and then refed the indicated diets. High-Suc, Chow, and + Chol represent mice refed with
the high-sucrose diet, the normal chow diet, and diets supplemented with 2% cholesterol, respectively. After treatment, livers of each group
were separately pooled, and 30 mg aliquots of the membrane fractions [for Pcsk9, Ldlr, the precursor forms of Srebps, and receptor-
associated protein (Rap)] or the nuclear extract fraction [for nuclear forms of Srebps and cAMP-response element binding protein (Creb)]
were subjected to SDS-PAGE and immunoblot analysis. P and N denote the precursor and nuclear forms of Srebps, respectively. B: Total
RNAs were isolated from pooled livers used for the immunoblot analyses, and cDNAs were prepared as described in Materials and Methods.
The cDNAs were subjected to real-time PCR with the primers for Srebp-2, Pcsk9, Ldlr, HMG-CoA reductase (Hmgcr), Srebp-1c, acetyl-CoA
carboxylase a (Acaca), fatty acid synthase (Fasn), and stearoyl-CoA desaturase-1 (Scd-1). Each value represents the amount of mRNA
(mean6 SD from triplicate reactions) relative to that in the nonfasted group, which was arbitrarily defined as 1. Cyclophilin was used as an
invariant control (data not shown). Similar results were obtained in three independent experiments.
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reduced the promoter activity in the absence of sterols,
and the sterol-dependent suppression of the promoter ac-
tivity was attenuated from ?95% to 41%. The role of the
SRE site in the sterol-dependent regulation of the PCSK9
promoter was supported by the observation that the
expression of the nuclear forms of SREBP-1a, -1c, or -2
significantly activated the promoter activities, whereas mu-
tation in SRE resulted in the loss of activation by SREBPs.
However, it is suggested that the presence of SRE alone
is insufficient for the sterol-dependent regulation of the
PCSK9 promoter, because construct D6, in which the SRE
site remained intact, lost its transcriptional activity. This
finding suggests that the nucleotide sequence between
2392 and the SRE site is important for the basal tran-
scriptional activity and sterol-dependent regulation of the
PCSK9 promoter. Interestingly, in this region of PCSK9
resides a hepatocyte nuclear factor-1 reported in the liver
fatty acid binding protein of mice (40). However, it is un-
certain whether hepatocyte nuclear factor-1 is critical for
the transcription of the PCSK9 promoter, based on the
observation by cotransfection assay (date not shown), al-
though no detailed study on this region was carried out
in this experiment. The Sp1 binding sites, which activate
the expression of the LDLR promoter synergistically with
SREBP-1 (41), were identified to be dispensable for the
sterol-dependent regulation of PCSK9 transcription.
The interaction of SREBPs with the SRE site in the PCSK9
promoter was verified by EMSA. The in vitro-translated
nuclear forms of SREBP-1a and SREBP-2 directly bound
to this SRE site specifically. Simply based on the result
shown in Fig. 5B, SREBP-2 is supposed to bind the SRE of
the PCSK9 promoter less tightly than SREBP-1a. It is un-
explainable why the in vitro-translated nuclear form of
SREBP-2 always gave the less clear band-shift on EMSA
than SREBP-1a in our repeated experiments, which were
carried out with varying concentrations of salt or detergent
in the reactions. However, it should be noted that the
intensity of the mobility-shifted band does not directly
represent the affinity of SREBPs to the SRE site, because
in vitro-translated SREBPs were not verified for their struc-
tures and functions to be unimpaired. For EMSA experi-
ments, we used in vitro-translated proteins without tag
sequence to exclude the effect on the mobility-retarded
band produced by the tag sequence. The absence of the
tag sequence made it impossible to directly compare the
amounts of in vitro-translated proteins used in EMSA, al-
though we confirmed the production of in vitro-translated
proteins with the expected molecular size by immunoblot
analysis using antigen-specific antibodies.
Sterol-dependent regulation of Pcsk9 was verified in
livers of mice under the nutritional manipulations. Fast-
ing dramatically decreased Pcsk9 protein and mRNA, and
refeeding restored the expression of Pcsk9 in livers of mice.
However, a diet supplemented with 2% cholesterol atten-
uated the restoration of the decreased expression of Pcsk9
observed in livers of fasted mice. Attenuation of Pcsk9
restoration by cholesterol correlated with the decrease in
the nuclear form of SREBP-2 by cholesterol, whereas the
nuclear form of Srebp-1 remained upregulated in livers of
mice refed cholesterol-supplemented diets. Additionally,
reciprocal changes in the expression of Ldlr protein were
observed clearly in the mice refed a chow diet. The pre-
dominant role of SREBP-2 in the sterol-dependent regu-
lation of Pcsk9 is supported indirectly by the observation that
cholesterol-supplemented diets do not decrease the expres-
sion of other SREBP-1 target genes, such as those encoding
Acaca, Fasn, and Scd-1. As reported by Costet et al. (17),
findings in this report do not exclude the possible in-
volvement of Srebp-1 in the regulation of Pcsk9 expression
in livers of mice during fasting and refeeding. This con-
cern is supported by our findings that fasting dramatically
downregulated the expression of Pcsk9 and that refeeding
a cholesterol-supplemented diet did not completely down-
regulated the expression of Pcsk9. It can be speculated that
both the absolute quantities of and the balance between
Srebp-1 and Srebp-2 determine the expression of Pcsk9.
Together, our current studies indicate that the expres-
sion of PCSK9 is regulated by SRBEPs at the transcriptional
level both in vitro and in vivo, and the predominant regu-
lator of sterol-dependent expression of PCSK9 is SREBP-2
in vivo. To elucidate the detailed mechanisms of regula-
tion of PCSK9 expression, additional studies will be re-
quired to characterize a mechanism that coordinates the
role of SREBPs on PCSK9 expression and to identify the
transcription factors other than SREBPs.
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